Company news
uniQure N.V. news in 2022
uniQure N.V.'s news releases, calls and decks from 2022, newest first.
uniQure announces positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adults with hemophilia B
December 15, 2022
uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event
November 28, 2022
uniQure announces FDA approval of first gene therapy for adults with hemophilia B
November 21, 2022
uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022
November 16, 2022
uniQure Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
November 1, 2022
uniQure Announces Multiple Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)
October 10, 2022
uniQure to Participate in Upcoming Industry Conferences in October
October 2, 2022
uniQure to Participate in Upcoming Industry Conferences in September
September 5, 2022
uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
August 7, 2022
uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
June 22, 2022
uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review
May 23, 2022
uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 1, 2022
uniQure Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress
May 1, 2022
European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B
March 27, 2022
uniQure Announces Completion of Patient Enrollment in the First Two Cohorts of its Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
March 20, 2022
uniQure Announces 2021 Financial Results and Highlights Recent Company Progress
February 24, 2022
uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease
February 6, 2022
Final Analysis of Pivotal HOPE-B Study Demonstrates Durable and Sustained Therapeutic Effect of Etranacogene Dezaparvovec Gene Therapy in Hemophilia B - Data Presented at EAHAD 2022
February 3, 2022
Calls in 2022
Decks in 2022
- Investor Presentation (August 2022)
Investor deck · 31 slides · August 2022
- EAHAD 2022
Conference · 14 slides · Feb 4, 2022